Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 46, Issue 2, 1997, Pages 192-198

  O'Rourke, Christine M ^a,b   Davis, Jo Ann ^a   Saltiel, Alan R ^a   Cornicelli, Joseph A ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; TROGLITAZONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 0031055079     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90301-2     Document Type: Article

References (33)

1. Saltiel AR, Horikoshi H: Thiazolidinediones: Novel insulin-sensitizing agents. Curr Opin Endocrinol Diabetes 2:341-347, 1995
2. Nolan JJ, Ludvik B, Beerdsen P, et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
3. Fujita T, Sugiyama Y, Taketomi S, et al: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-ethylcyclohexyl-methoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
4. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
5. Chang AY, Wyse BM, Gilcrhist BJ, et al: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32:830-838, 1983
6. Stevenson RW, Hutson NJ, Krupp MN, et al: Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
7. Fujiwara T, Okuno A, Yoshioka S, et al: Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44:486-490, 1995
8. Horikoshi H, Fujiwara T, Yoshioka T, et al: Pharmacological characteristics of new antidiabetic agent CS-045 in diabetic animals, in Shafrir E (ed): Lessons From Animal Diabetes III. London, UK, Smith-Gordon, 1990, pp 320-324
9. Fujiwara T, Wada M, Fukuda K, et al: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40:1213-1218, 1991
10. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hyperglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
11. Iwamoto Y, Kuzuya T, Matsuda A, et al: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
12. Lee M, Miles PDG, Khoursheed M, et al: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
13. Kraegen EW, James DE, Jenkins AB, et al: A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding in rats. Metabolism 38:1089-1093, 1989
14. Goto Y, Suzuki K, Sasaki M, et al: GK rat as a model of nonobese, noninsulin-dependent diabetes. Selective breeding over 35 generations, in Shafrir E (ed): Lessons From Animal Diabetes II. London, UK, Smith-Gordon, 1988, pp 301-303
15. Goto Y, Suzuki K, Ono T, et al: Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 246:29-31, 1988
16. Portha B, Serradas P, Bailbe D, et al: B-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 40:486-491, 1991
17. + channels is impaired in B-cells of the GK rat. Diabetes 42:1446-1453, 1993
18. Giroix MH, Sener A, Portha B, et al: Preferential alteration of oxidative relative to total glycolysis in pancreatic islets of two rat models of inherited or acquired type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:305-309, 1993
19. Ostenson CG, Abdel-Halin SM, Rasschaert J, et al: Deficient activity of FAD-linked glycerophosphate dehydrogenase in islets of GK rats. Diabetologia 36:722-726, 1993
20. Sener A, Malaisse-Lagae F, Ostenson C, et al: Metabolism of endogenous nutrients in islets of Goto-Kakizaki (GK) rats. Biochem J 296:329-334, 1993
21. Bisbis S, Bailbe D, Tormo MA, et al: Insulin resistance in the GK rat: Decreased receptor number but normal kinase activity in liver. Am J Physiol 265:E807-E813, 1993
22. Suzuki K, Goto Y, Toyota T: Spontaneously diabetic GK (Goto-Kakizaki) rats, in Shafrir (ed): Lessons From Animal Diabetes IV. London, UK, Smith-Gordon, 1993, pp 107-116
23. Farese RV, Standaert ML, Yamada K, et al: Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic, Goto-Kakizaki rats. Proc Natl Acad Sci USA 91:11040-11044, 1994
24. Hsu WH, Berlin SI, Dellmann HD, et al: Xylazine-ketamine-induced anesthesia in rats and its antagonism by yohimbine. J Am Vet Med Assoc 189:1040-1043, 1986
25. Kraegen EW, James DE, Bennett SP, et al: In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol 245:E1-E7, 1983
26. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985
27. Burnol A, Leturque A, Ferre P, et al: A method for quantifying insulin sensitivity in vivo in the anesthetized rat: The euglycemic insulin clamp technique coupled with isotopic measurement of glucose turnover. Reprod Nutr Dev 23:429-435, 1983
28. DeFronzo RA, Jordan DT, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
29. Shafrir E: Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 8:179-208, 1992
30. Oakes MD, Kennedy CJ, Jenkins AB, et al: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
31. Ciaraldi TP, Gilmore A, Olefsky JM, et al: In vitro studies of the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
32. Herberg L, Coleman DL: Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59-99, 1977
33. Bowen L, Steven PP, Stevenson R, et al: The effect of CP-68772, a thiazolidine derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40:1025-1030, 1991